![[September 2021 Newsletter] Curi News – Mantarray Detection of Drug-induced Contractile Changes](https://images.squarespace-cdn.com/content/v1/5ea9dcad38347f7b8405d2f9/1634069219121-QZVRUTU9WQJE5PHWBX55/CuriBio_Mantarray-Dox-Graphs-02.jpg)
On May 13, 2021, Curi Bio’s CSO, Dr. Nicholas Geisse, was a panelist for Device Connect by Life Science Washington hosted by Product Creation Studio. We wanted to share the great discussion here for anyone who missed. Enjoy!
Read More
The Mantarray platform was announced among the finalists within the AI and Data category of Fast Company’s World Changing Ideas Awards 2021. The Mantarray enables the discovery, safety, and efficacy testing of new therapeutics by providing parallel analysis of 3D engineered muscle tissues with adult-like functional profiles, bringing clinically-relevant functional data into the earliest stages of preclinical testing of new medicines.
Read More
SEATTLE – Curi Bio, Inc. announced today that their Mantarray™ platform won a Bronze Edison Award. Named after Thomas Alva Edison, the Edison Awards have recognized and honored some of the most innovative new products, services, and business leaders in the world since 1987.
Read More
Curi Bio Inc., a leading developer of human stem cell-based platforms for drug discovery, announced today it has raised $6 million in a Series A financing round.
Read More
Curi Bio is honored to be announced a 2020 Tibbetts Award Winner by the U.S. Small Business Administration! This award recognizes our critical role in successfully driving high-tech innovation within the U.S. with our next-generation human stem cell platforms. #sbirTibbetts
Read More
ASCB 2020 Subgroup & Tech Talk | 384-well & 96-well NanoSurface Plates | Cytostretcher
Read More
Curi Bio’s Chief Science Officer Dr. Nicholas Geisse has been awarded the Big Idea of the Year by Xconomy, an award that honors the people, companies, and organizations who are advancing transformative and revolutionary ideas in life sciences and healthcare.
Read More
Curi’s Mantarray platform enables the discovery, safety, and efficacy testing of new therapeutics by providing parallel analysis of 3D engineered muscle tissues with adult human-like functional profiles.
Read More
Curi’s ComboMat platform leverages a combination of cues—including a proprietary microRNA cocktail—to drive the functional development and maturation of cardiomyocytes with applications in drug discovery, disease modeling, and safety and efficacy screening.
Read More
NanoSurface Biomedical, a leading developer of human stem cell-based biotechnology products, today announced a comprehensive rebrand, including a change of the company’s name to Curi Bio. The company has also relocated its corporate headquarters to a new 5,000 square-foot BSL-2 laboratory and office space in downtown Seattle.
Read More
NanoSurface Bio exclusively licenses heart-on-chip technology, launched by the NCATS research team to the Space Station on the SpaceX Dragon, for commercialization back on Earth.
Read MoreNanoSurface Biomedical awarded $1.9M in new funding from the NIH, bringing total non-dilutive NIH funding awarded to NanoSurface to $3.1M.
Read More
NanoSurface Biomedical announced today the launch of the 384-well NanoSurface Plate™, the newest and highest-throughput offering of the NanoSurface Plates™ product line.
Read MoreNanoSurface Bio announces that its Chief Science Officer, Dr. Nicholas Geisse, will present at Biotech Showcase 2020 held at the Hilton San Francisco Union Square in San Francisco during the JP Morgan Healthcare Conference. The presentation is scheduled for the second day of the event on Tuesday, January 14th at 4:45 PM PT.
Read More
NanoSurface Biomedical announced today that it has acquired Silene Biotech, a Seattle biotechnology company focused on stem cell banking and services. This acquisition expands NanoSurface’s capabilities in developing human stem cell-based platforms and technologies to accelerate the development of new drugs.
Read More